As of Monday, December 8, 2025, Gilead Sciences, Inc. (NASDAQ: GILD) sits near the upper end of its 52‑week range, supported by strong HIV franchises, new long‑acting prevention drugs, high‑profile cancer data at ASH 2025 and a steady dividend. At the same time, investors are weighing slowing COVID‑19 sales, competitive oncology pressures and policy risk.
Below is a structured look at today’s price action, the latest news flow dated December 8, 2025, analyst forecasts and the medium‑term investment narrative around Gilead Sciences stock.
Gilead Sciences (GILD) stock price on December 8, 2025
Gilead shares are trading around $121 per share in today’s session. Real‑time data show GILD at about $121.07, with intraday trading between roughly $120.9 and $122.3.
Daily historical data for December 8, 2025 indicate:
- Open: $120.98
- High: $122.37
- Low: $120.59
- Close: $121.09
- Move on the day: roughly ‑0.1%
- Volume: ~2.15 million shares. [1]
That close leaves Gilead about 6% below its 52‑week high of $128.70, reached on November 20, 2025. [2]
Recent sessions have been a bit choppy:
- Dec 4: ‑1.9% to $122.62 [3]
- Dec 5: ‑1.14% to $121.22, underperforming peers like Pfizer and Abbott [4]
- Dec 8: essentially flat to slightly down, reflecting a pause after a strong multi‑year run.
Overall, GILD is trading near its recent highs, with relatively modest volatility and volumes close to or slightly below its 50‑day average on quieter days. [5]
The most important Gilead stock news dated December 8, 2025
1. Fresh 13F filings show ongoing institutional interest
A notable cluster of institutional activity headlines hit on December 8, 2025:
- SVB Wealth LLC disclosed the purchase of 35,296 Gilead shares, adding to its position in the Q2 13F filings. [6]
- WINTON GROUP Ltd opened a new 45,315‑share position worth about $5.0 million, underscoring interest from quantitative and multi‑strategy funds. [7]
- L2 Asset Management LLC more than doubled its holdings, adding 28,592 shares to reach 56,516 shares total. [8]
- Natixis also reported buying Gilead shares, in a filing flagged the same day. [9]
In a separate December 7 filing, Brown Advisory trimmed its stake by about 6.3% to 256,539 shares, but this sits against a backdrop of heavy overall institutional ownership: roughly 83.7% of Gilead shares are held by institutions, including major positions from Norges Bank and T. Rowe Price. [10]
The net takeaway: institutional ownership remains high, with new buyers offsetting some profit‑taking from long‑time holders.
2. Short interest update: modest bearish bets, trending lower
Also dated December 8, 2025, a Benzinga short‑seller update shows: [11]
- Short interest: 17.01 million shares
- Share of float sold short:1.37%
- Change vs last report:‑5.52% (short interest has come down)
- Days to cover: roughly 2.3 days at recent trading volumes
Those numbers indicate modest bearish positioning that is actually easing, not a heavily shorted value trap. For many investors, a low but not zero short interest suggests some skepticism but no large, coordinated bet against the stock.
3. ASH 2025: cell therapy and CAR‑T headlines keep oncology in focus
Gilead and its Kite subsidiary are in the spotlight at the American Society of Hematology (ASH) 2025 meeting in Orlando, with multiple data updates across their CAR‑T and cell‑therapy portfolio:
- A Gilead/Kite investor release outlines 21 abstracts at ASH 2025, including translational medicine work on CAR‑T‑associated neurotoxicity and multiple real‑world and clinical datasets for Yescarta (axicabtagene ciloleucel) and Brexucabtagene autoleucel in various lymphomas. Several of those are presented on December 8, 2025. [12]
- A separate Kite press release highlights new results from the pivotal iMMagine‑1 trial of anitocabtagene autoleucel (“anito‑cel”) in multiple myeloma, positioning the therapy as a potential future competitor in a crowded CAR‑T space. [13]
- Trade‑press coverage from BioSpace frames Gilead and Johnson & Johnson as “CAR‑T leaders” at ASH 2025, particularly in multiple myeloma. [14]
For Gilead’s stock story, the ASH news reinforces:
- Oncology is a real, but still emerging, second growth pillar alongside HIV.
- Cell therapy remains scientifically promising but commercially uneven, which is part of why earnings contributions from oncology lag HIV today. [15]
4. Yeztugo and long‑acting HIV prevention stay in the spotlight
Gilead’s twice‑yearly HIV prevention injection, marketed as Yeztugo, continues to draw attention as one of 2025’s standout U.S. drug approvals:
- Yeztugo, based on lenacapavir, is the world’s only twice‑yearly injectable PrEP shot approved by the FDA, and can be used across genders. [16]
- In a pivotal late‑stage trial, a PharmaVoice summary notes that the injection prevented HIV infection in 100% of the 2,134 participants who received it, giving it a compelling efficacy profile versus both oral PrEP (Truvada, Descovy) and rival long‑acting options that require more frequent dosing. [17]
Financially, Yeztugo is still in its early launch phase:
- Q3 2025 saw $39 million in Yeztugo revenue, enough to meet Wall Street expectations but below increasingly bullish hopes. [18]
- Gilead’s CEO has flagged efforts to expand payer coverage to around 90% by mid‑2026, which will be critical for long‑term uptake. [19]
For Gilead stock, Yeztugo and the broader lenacapavir franchise underpin the argument that HIV cash flows can extend well into the 2030s, even as older regimens face future generic pressure. [20]
5. Smaller but notable: breast cancer initiatives and patient‑support efforts
On December 8, 2025, PR Newswire carried news of a new symptom‑management guide for people undergoing metastatic breast cancer treatment, produced by Viver Health with support from Gilead. The guide aims to give patients and caregivers practical tools for managing complex treatment‑related side effects. [21]
The release also reiterates Gilead’s broader oncology commitment and references a planned $32 billion investment to strengthen its U.S. presence, underscoring the company’s willingness to spend aggressively on cancer programs, infrastructure and access initiatives. [22]
Earnings, guidance and dividend: the fundamental backdrop
Q3 2025: strong EPS, mixed quality
Gilead’s latest reported quarter (Q3 2025, released October 30) remains the reference point for today’s fundamental debate:
- Total revenue: $7.77 billion, up 3% year‑on‑year and ahead of analyst expectations around $7.45 billion. [23]
- HIV sales: up 4% to $5.3 billion, boosted by prevention products including Yeztugo. [24]
- Other liver disease medicines: up about 12%, partly offsetting declines elsewhere. [25]
- COVID‑19 therapy Veklury and some cancer cell therapies: down significantly, contributing to a 2% decline in overall product sales to $7.3 billion. [26]
- Adjusted EPS:$2.47, versus $1.00 a year earlier, helped by a $400 million intellectual property sale and lower expenses. [27]
Analysts have mostly described the quarter as a headline beat, but with some lower‑quality components, since one‑time items and cost cuts did a lot of the work. [28]
Updated 2025 guidance and Street expectations
Management has now raised guidance twice in 2025, and currently expects: TechStock²+1
- Product sales: $28.4–$28.7 billion
- Product sales excluding Veklury: $27.4–$27.7 billion
- GAAP EPS: $6.65–$6.85
- Non‑GAAP EPS: $8.05–$8.25
Independent estimates converge on similar numbers:
- Seeking Alpha’s compiled consensus pegs 2025 EPS around $8.17 and revenue about $29.2 billion, rising toward $30.7 billion in 2026 with mid‑single‑digit EPS growth to roughly $8.9. [29]
At today’s ~$121 share price and mid‑point non‑GAAP EPS guidance (~$8.15), Gilead trades around 15x forward 2025 earnings, which is below many large‑cap growth biotechs but not “deep value” territory. (Calculation approximate and for illustration only.)
Dividend profile
For income‑oriented investors, Gilead is firmly in dividend‑payer territory:
- The board increased the quarterly dividend to $0.79 per share in 2025, or about $3.16 annualized. [30]
- That equates to a forward yield of roughly 2.5–2.7% at current prices, depending on the exact intraday share price. [31]
- The next dividend is expected to go ex‑dividend on December 15, 2025, with payment expected near the end of the month — an immediate timing consideration for dividend investors. [32]
- Dividend research outfits generally see the payout ratio in the high‑30% range, covered by strong free cash flow. TechStock²
Wall Street’s view: ratings and price targets for GILD
Across major data providers, Gilead carries a broadly positive but not euphoric rating profile.
Consensus ratings
- MarketBeat reports 2 Strong Buy, 22 Buy and 3 Hold ratings, for an overall “Moderate Buy” consensus. TechStock²+2MarketBeat+2
- StockAnalysis aggregates 22 analysts with a simple “Buy” consensus. [33]
- Public.com lists 19 analysts and also assigns a Buy consensus as of December 8, 2025. [34]
- MarketWatch summarises the average recommendation as “Overweight”, based on 30 ratings. [35]
Put simply: most analysts like Gilead, but it’s usually framed as a steady compounder rather than a hyper‑growth play.
Price targets
There is some spread in one‑year price targets, but the mid‑point is only modestly above today’s level:
- MarketBeat: average target $130.65, range $105–$153, implying around 8% upside from roughly $121–122. [36]
- StockAnalysis: average target $123.45, range $80–$150, implying about 2% upside. [37]
- MarketWatch: average target $132.22. [38]
- Public.com: 2025 price prediction around $125.05. [39]
- A Benzinga compilation (including slightly older targets) shows a consensus around $116.1, with a high of $150 from JPMorgan and a low of $69 from HSBC, reflecting differing views on long‑term HIV durability and oncology execution. [40]
Recent broker moves captured in pre‑market coverage include:
- Truist Securities: Buy, target trimmed from $145 to $140.
- Scotiabank: “Sector Outperform,” $140 target.
- Needham: Buy, target raised from $133 to $140.
- Cantor Fitzgerald: Overweight, target $135. TechStock²
The broad message: Street price targets cluster in the mid‑$120s to around $140, suggesting mid‑single‑digit to low‑double‑digit upside from current levels, not a consensus call for a dramatic re‑rating.
Growth drivers: HIV, oncology and inflammation
HIV: Biktarvy, lenacapavir and long‑acting strategies
Gilead remains a global leader in HIV treatment and prevention. Its HIV franchise continues to grow:
- Biktarvy remains a cornerstone treatment, with long‑term data (BICSTaR) from real‑world settings showing durable efficacy and safety over five years. [41]
- A patent settlement over Biktarvy is expected to delay generic versions into the 2030s, giving Gilead more time to harvest cash flows and reinvest into newer therapies. [42]
- Lenacapavir is the backbone of Gilead’s long‑acting HIV pipeline, with data presented at CROI 2025 and EACS 2025, including an investigational twice‑yearly treatment regimen combining lenacapavir with broadly neutralizing antibodies, which met primary endpoints and received FDA Breakthrough Therapy designation. [43]
- Yeztugo’s approval as a twice‑yearly PrEP injection gives Gilead a significant edge in adherence and convenience compared with oral PrEP and some competitor injectables. [44]
Taken together, these pieces underpin the argument that HIV can remain a durable, high‑margin cash engine for Gilead well beyond the current decade.
Oncology and cell therapy: Kite, Yescarta and anito‑cel
Gilead’s oncology strategy spans small molecules, antibody‑drug conjugates and cell therapy: [45]
- Yescarta (axi‑cel) is already approved for several large B‑cell lymphoma indications, with new real‑world and clinical data at ASH 2025 exploring long‑term outcomes, resource utilization and factors that drive durable remissions. [46]
- Brexucabtagene autoleucel continues to generate follow‑up results in mantle cell lymphoma and other blood cancers. [47]
- Anitocabtagene autoleucel (“anito‑cel”), a next‑generation BCMA‑targeting CAR‑T for multiple myeloma, is emerging as a key late‑stage asset; new data from the pivotal iMMagine‑1 study at ASH 2025 highlight its potential to compete in a crowded space. [48]
- On the solid‑tumor side, Trodelvy (sacituzumab govitecan) has delivered a major win in first‑line triple‑negative breast cancer but mixed data in HR+/HER2‑negative disease, suggesting a more nuanced growth trajectory than bulls once hoped. TechStock²
Oncology is still smaller than HIV in revenue terms, and recent quarters have seen some cell‑therapy sales pressure, but the scientific and clinical momentum is real. [49]
Inflammation and other areas
Gilead is also building out an inflammation and immunology pipeline, aiming to diversify away from pure virology:
- The inflammation portfolio now includes 13 assets from preclinical to Phase 2, plus an approved therapy for primary biliary cholangitis (PBC). [50]
- Corporate materials emphasize a strategy of “bold ambitions across virology, oncology and inflammation”, with more than 10 potential first‑in‑class Phase 2 and Phase 3 programs highlighted in its “Gilead in 2025” investor presentation. [51]
For investors, this diversification is key: if HIV growth eventually slows, oncology and inflammation need to step up to keep revenue and EPS expanding.
Market sentiment and valuation: is GILD cheap or fairly priced?
Different valuation frameworks give very different answers:
- A Simply Wall St discounted cash‑flow (DCF) model estimates that Gilead is roughly 50–55% undervalued, implying substantial upside if its long‑term cash flows materialize as expected. [52]
- The same analysis estimates Gilead’s current P/E around 18.5x, compared with a so‑called “fair” P/E of 28.2x, again suggesting undervaluation relative to its own risk/return profile and peers. [53]
- By contrast, valuation frameworks such as GuruFocus’s “GF Value” (as summarized in ts2.tech’s pre‑market note) point to a fair value near the low $90s, which would imply downside from current levels. TechStock²
Short‑term trading models also weigh in: StockInvest.us, for example, projected a “fair” opening price of $121.38 for December 8, 2025 — essentially in line with where the stock actually opened. [54]
The upshot:
- Valuation is not extreme in either direction on simple metrics, but
- Scenario‑based and DCF models can justify either significant upside or meaningful downside, depending on how one handicaps HIV durability, oncology execution and pricing policy risks.
Key risks and watch‑points for Gilead stock
Drawing on today’s coverage and recent analyst commentary, investors are focusing on several major risk areas: TechStock²+2Reuters+2
- HIV concentration and pricing pressure
HIV still accounts for a large share of sales. Even with Biktarvy protection into the 2030s and promising long‑acting options, Gilead remains exposed to changes in treatment guidelines, generic challenges, competitive launches and reimbursement pressures in PrEP. - Oncology competition and uneven data
Trodelvy faces competition from other TROP2‑targeting antibody‑drug conjugates, while CAR‑T competitors are also advancing in lymphoma and myeloma. Any safety surprises or negative readouts at meetings like ASH can weigh on sentiment. - R&D and deal‑execution risk
Gilead has been active in deals, such as the Interius in‑vivo CAR‑T acquisition and a $750 million collaboration with Kymera on molecular “glue” degraders. These moves are strategically bold but early‑stage, and management has already acknowledged they dilute 2025 EPS by some amount with uncertain long‑term payoffs. TechStock²+1 - Policy and pricing overhang
Gilead is highly exposed to U.S. drug‑pricing reforms, including Medicare negotiations under the Inflation Reduction Act, and to global HIV funding trends. Any adverse changes could pressure margins or slow uptake of premium‑priced innovations like Yeztugo. - Positioning after a strong multi‑year run
After a sustained rally that brought shares within a few percent of all‑time highs, some large funds (e.g., Brown Advisory, Federated Hermes) have trimmed exposure, setting the stage for profit‑taking if guidance or payer updates disappoint. [55]
So is Gilead Sciences stock a buy right now?
From the mosaic of December 8, 2025 news, numbers and forecasts, a few themes stand out:
- Defensive growth profile: Gilead combines recurrent, relatively resilient HIV cash flows with a growing dividend, moderate EPS growth and a strong balance sheet. [56]
- Pipeline‑driven optionality: Long‑acting HIV (Yeztugo, lenacapavir regimens), a deepening oncology and cell‑therapy suite, and a budding inflammation portfolio offer upside if execution remains solid and data stays favorable. [57]
- Valuation that many see as reasonable: Most brokers rate the stock a Buy/Overweight, with price targets modestly above today’s levels; some DCF models see much more upside, while more conservative frameworks highlight potential downside. [58]
- Risks that are real but largely known: HIV concentration, policy risk, intense oncology competition and execution risk around acquisitions are all well‑flagged in recent analyses.
For short‑term traders, December 8’s session is mainly about how the market digests ASH 2025 data, the latest short‑interest decline and any broker commentary that follows. [59]
For longer‑term investors, the question is whether you believe:
- Gilead can extend and expand HIV earnings via long‑acting prevention and treatment,
- Oncology and inflammation can scale enough to offset eventual HIV headwinds, and
- The company can navigate pricing and policy challenges while maintaining dividend growth and disciplined capital allocation.
If those boxes are ticked in your personal framework, the current setup looks like a steady, high‑cash‑flow pharma with moderate upside and income appeal. If you’re more skeptical about HIV durability or oncology execution, the stock may look closer to fully valued.
Important: This article is for information and general commentary only and does not constitute investment advice or a recommendation to buy or sell any security. Always do your own research and, where appropriate, consult a licensed financial adviser who understands your individual circumstances.
References
1. stockanalysis.com, 2. www.marketwatch.com, 3. www.marketwatch.com, 4. www.marketwatch.com, 5. www.marketwatch.com, 6. www.marketbeat.com, 7. www.marketbeat.com, 8. www.marketbeat.com, 9. www.marketbeat.com, 10. www.marketbeat.com, 11. www.benzinga.com, 12. investors.gilead.com, 13. www.biospace.com, 14. www.biospace.com, 15. www.reuters.com, 16. www.facebook.com, 17. www.pharmavoice.com, 18. www.reuters.com, 19. www.reuters.com, 20. www.gilead.com, 21. www.prnewswire.com, 22. www.prnewswire.com, 23. www.reuters.com, 24. www.reuters.com, 25. www.reuters.com, 26. www.reuters.com, 27. www.reuters.com, 28. www.reuters.com, 29. seekingalpha.com, 30. finance.yahoo.com, 31. finance.yahoo.com, 32. finance.yahoo.com, 33. stockanalysis.com, 34. public.com, 35. www.marketwatch.com, 36. www.marketbeat.com, 37. stockanalysis.com, 38. www.marketwatch.com, 39. public.com, 40. www.benzinga.com, 41. www.gilead.com, 42. www.biopharmadive.com, 43. www.gilead.com, 44. www.pharmavoice.com, 45. www.gilead.com, 46. investors.gilead.com, 47. investors.gilead.com, 48. www.biospace.com, 49. www.reuters.com, 50. www.gilead.com, 51. www.gilead.com, 52. simplywall.st, 53. simplywall.st, 54. stockinvest.us, 55. www.marketbeat.com, 56. www.reuters.com, 57. www.gilead.com, 58. www.marketbeat.com, 59. www.biospace.com
